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Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with cancers in immunocom-
promised populations. EBV establishes a latent infection and immortalizes and transforms B lymphocytes.
Several latent proteins have profound effects on cellular growth, including activation of NF-B, phosphatidyl-
inositol 3-OH kinase (PI3K) signaling, and notch signaling. Activation of PI3K can affect the activity of
-catenin, the target of the wnt signaling pathway. Deregulation of -catenin is associated with a number of
malignancies. To determine if -catenin is regulated by EBV infection, EBV-infected cells were examined for
-catenin levels and localization. -Catenin was increased in EBV-positive tumor cell lines compared to
EBV-negative lines, in EBV-infected Burkitt’s lymphoma cell lines, and in EBV-transformed lymphoblastoid
cell lines (LCL). In contrast to wnt signaling, EBV consistently induced the accumulation of -catenin in the
cytoplasm but not the nucleus. The -catenin regulating kinase, glycogen synthase kinase 3 (GSK3), was
shown to be phosphorylated and inactivated in EBV-infected lymphocytes. Inactivated GSK3 was localized to
the nucleus of EBV-infected LCL. Neither the cytoplasmic accumulation of -catenin nor the nuclear inacti-
vation of GSK3 was affected by the inhibition of PI3K signaling. These data indicate that latent infection with
EBV has unique effects on -catenin signaling that are distinct from activation of wnt and independent of its
effects on PI3K.
Epstein-Barr Virus (EBV) is the causative agent of lympho-
mas that develop in immunosuppressed patients, such as post-
transplant lymphoma and a significant percentage of AIDS-
associated lymphomas (20, 37). EBV is also consistently
detected in the endemic form of Burkitt’s lymphoma (BL) and
found with varying incidence in distinct subtypes of Hodgkin’s
disease (HD). In developing countries, it is detected in almost
all cases of HD. EBV is a major factor in the development of
the epithelial cancers nasopharyngeal carcinoma (NPC) and
gastric carcinoma.
The expression pattern of EBV latent genes differs depend-
ing upon the state of the cell, whether it is resting or activated,
as well as immune surveillance. Three distinct patterns of la-
tent EBV gene expression have been identified in tumor sam-
ples, and cell lines that mimic these profiles offer attractive
model systems for studying the contributions of different EBV
proteins to cancer development. During type I latency, char-
acteristic of BL, only EBV nuclear antigen 1 (EBNA1), tran-
scripts from the BamHI-A region of the viral genome, and
small nonpolyadenylated RNAs, known as EBERs, are ex-
pressed. Latency type II, characteristic of NPC and HD, is
characterized by expression of EBNA1, the EBERs, BamHI-A
transcripts, and latent membrane proteins 1, 2A, and 2B
(LMP1, LMP2A, and LMP2B, respectively). During type III
latency, which is characteristic of posttransplant lymphoma,
EBNAs 1, 2, 3A, 3B, 3C, and LP, BamHI transcripts, EBERs,
LMP1, LMP2A, and LMP2B are expressed.
Several EBV proteins have profound effects on cellular gene
expression, growth control, and signaling. The EBNA proteins,
EBNA2 and EBNA3A, -B, and -C, and RK-BARF0 impinge
on Notch signaling (23). LMP1 interacts with tumor necrosis
receptor-associated factors to activate NF-B and JNK, and
LMP2A inhibits B-cell signaling and activates the phosphati-
dylinositol 3-OH kinase (PI3K) pathway.
The wnt/wingless signaling cascade is an important pathway
that is activated in a number of cancers. -Catenin, a transcrip-
tional regulatory factor, is a critical component of the wnt
signaling pathway (35). Stabilized or free -catenin can trans-
locate to the nucleus and bind transcription factors, such as the
T-cell factor (Tcf) or lymphocyte enhancer factor (Lef), to
activate transcription. In Xenopus laevis and Drosophila mela-
nogaster systems, -catenin–Tcf/Lef complexes regulate a num-
ber of important developmental programs and genes. In mam-
malian cells, -catenin–Tcf/Lef complexes regulate the
expression of a number of proto-oncogenes, including c-myc
(15) and cyclin D1 (44, 46), as well as genes important for
growth and tumor progression, such as MMP7 (5), PPAR
(14), gastrin (21), connexin 43 (49), and WISP proteins (34).
-Catenin can regulate leukemic cell adhesion, proliferation,
and survival (3), and Tcf and Lef have roles in B- and T-cell
development (32, 40, 50). However, a targeted -catenin
knockout mouse model suggests that -catenin is not essential
for these processes (4). The specific roles of -catenin in lym-
phocyte proliferation and the development of lymphoma are
unknown.
-Catenin and glycogen synthase kinase 3 (GSK3) are
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retained in the cytoplasm in a protein complex with adenoma-
tous polyposis coli (APC) and axin (33, 35). Phosphorylation of
-catenin on the amino-terminal serine and threonine residues
by GSK3 results in its degradation by ubiquitin-dependent
mechanisms. An important step in the regulation of -catenin
is phosphorylation of GSK3 and, in the presence of a wnt
signal, GSK3 is phosphorylated and inactivated or seques-
tered, resulting in the stabilization of -catenin. Mutations
affecting the GSK3 phosphorylation sites on -catenin or
-catenin binding sites on APC occur in greater than 90% of
colon cancers (22). Deregulation of the wnt/wingless pathway
is also associated with skin cancer (1), hepatoblastoma (45),
ovarian endometrioid adenocarcinoma (55), and medulloblas-
toma (28, 35).
A recent study from our lab revealed that in epithelial cells
EBV LMP2A activates signaling pathways that lead to -cate-
nin stabilization, nuclear translocation, and -catenin-depen-
dent transcriptional activation. LMP2A has been shown to
activate PI3K signaling, inducing the phosphorylation and ac-
tivation of Akt, and phosphorylation of Akt targets, forkhead
transcription factor family members, and GSK3 (29, 41, 42).
While the increased -catenin in the cytoplasm of LMP2A-
expressing cells was independent of PI3K signaling, the nuclear
translocation of -catenin was inhibited by inactivation of
PI3K.
The EBV oncoprotein, LMP1, also activates PI3K signaling
(6); however, any role for LMP1 in -catenin regulation has yet
to be established. Interestingly, Kaposi’s sarcoma-associated
herpesvirus infection latency-associated nuclear antigen regu-
lates the activity of GSK3 by binding and sequestering it in
the nucleus, resulting in activation of -catenin-responsive re-
porter plasmids (11–13). A comparison of EBV-infected lym-
phoblastoid cell lines (LCLs) detected elevated -catenin lev-
els in type III latency compared to type I (43).
In this study, expression of -catenin was analyzed in a panel
of EBV-negative and EBV-positive cell lines, in EBV-negative
BL cell lines infected with EBV, and in low-passage LCLs
transformed with EBV. In contrast to regulation of -catenin
by LMP2A in epithelial cells (29), increased cytoplasmic
-catenin did not correlate with increased nuclear -catenin.
However, there was a striking increase in the phosphorylation
and nuclear localization of the -catenin regulatory kinase
GSK3 that was independent of PI3K activation in EBV-pos-
itive cells. These data indicate that in B cells EBV infection
induces phosphorylation and nuclear localization of GSK3
without increased nuclear -catenin. This suggests that -cate-
nin-dependent gene expression is not activated during EBV
infection of B lymphocytes. However, the striking translocation
of GSK3 to the nucleus suggests that other targets of GSK3
are likely affected.
MATERIALS AND METHODS
Cell culture. Cell lines were maintained in RPMI 1640 (Gibco) supplemented
with antibiotic-antimycotic mixture and 10% (vol/vol) heat-inactivated fetal bo-
vine serum for most cell lines and 15% fetal bovine serum for LCL 5000 and
5077. Jurkat cells are immature T lymphocytes derived from acute lymphoblastic
leukemias. RAJI cells are an EBV-positive mature B-cell BL-derived cell line.
DG75 is an EBV-negative BL cell line. HL60 is an EBV-negative promyelocytic
leukemia cell line. BJAB is an EBV-negative high-grade B-cell lymphoma. B95-8
is a marmoset LCL transformed with B95-8 virus. CB-B95-8 is an umbilical cord
peripheral blood lymphocyte cell line transformed with B95-8 EBV. P3HR1 is a
Jijoye-derived BL cell line latently infected with P3HR1 virus containing a
deletion of the EBNA2 gene within the viral genome.
BL30 and BL41 are EBV-negative BL cell lines. BL30/B95-8 and BL41/B95-8
are infected with B95-8 virus, while BL30/P3HR1 and BL41/P3HR1 are infected
with P3HR1 virus. Peripheral blood lymphocyte (PBL) pools PBL 5000 and PBL
5077 and LCL lines LCL 5000 and LCL 5077 were procured from the University
of North Carolina—Chapel Hill Lineberger Comprehensive Cancer Center Tis-
sue Culture Facility. LCL 5000 and 5077 are transformed with EBV strain B95-8.
Cell harvesting and fractionation. Cell lines were grown in 75-cm2 tissue
culture flasks to 3  106 cells/ml. Cells treated with PI3K inhibitor were grown
in the presence of either LY294002 (50 M; Calbiochem) or the vehicle control,
dimethyl sulfoxide (DMSO; Sigma) for 24 h prior to harvesting. Typically, 5 
107 cells were harvested by centrifugation and washed with ice-cold phosphate-
buffered saline (Gibco). One-fifth or 107 cells were used to make whole-cell
lysates by centrifugation and lysis in 100 l of RIPA buffer (10 mM Tris-HCl [pH
8.0], 140 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate [SDS], 1%
deoxycholic acid, and protease and phosphatase inhibitors [Sigma]). The remain-
ing 4  107 cells were pelleted by centrifugation, resuspended in 350 l of buffer
A (20 mM HEPES [pH 7.5], 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM
dithiothreitol, and protease and phosphatase inhibitors), and incubated on ice
for 15 min. Cells were lysed by addition of 10% NP-40 to a final concentration
of 1% and vortexed for 1 min. Nuclei were pelleted by centrifugation for 10 min
at 1,600  g at 4°C. The supernatant cytosolic fraction was transferred to a new
tube, and the nuclear pellet was washed one time with 400 l of buffer A and
pelleted for 10 min at 1,600  g at 4°C. Nuclei were solubilized by addition of one
pellet volume of NE buffer (20 mM Tris [pH 8.0], 420 mM NaCl, 1.5 mM MgCl2,
0.2 mM EDTA, 25% glycerol, and protease and phosphatase inhibitors), fol-
lowed by one-fourth pellet volume of 5 M NaCl and one pellet volume of NE
buffer and vortexing.
Western blotting. Cell lysates were clarified by centrifugation and quantitated
with a Bio-Rad DC protein assay system (Bio-Rad). Samples were then boiled in
SDS sample buffer, and indicated amounts of proteins were separated using 10%
acrylamide SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and trans-
ferred to nitrocellulose membranes for Western blotting analysis. Primary anti-
bodies used included actin (I-19), PARP (H-250), and GRP-78 (N-20) (all from
Santa Cruz), phospho-GSK3 (Ser9; Cell Signaling Technology), -catenin (BD
Transduction Laboratories), GSK3 (Upstate Biotechnology), CS1-4 (anti-LMP1;
Dako), and PE2 (anti-EBNA2 mouse monoclonal) (53). Antibody-bound pro-
teins were detected with horseradish peroxidase-conjugated secondary antibod-
ies (Amersham Pharmacia and Dako) and the Pierce Supersignal West Pico
system (Pierce) followed by exposure to film.
Plasmids and RNA probes. -Catenin cDNA was synthesized from total RNA
isolated from C33A, a human cervical carcinoma cell line, with the BCTRNP3.2
primer (GCCAAGCTTGCCAGTATGATGAGCTTGCTTTC) using Super-
Script II RNase H- reverse transcriptase (Invitrogen) according to the manufac-
turer’s directions. cDNA was then amplified with primers BCTRNP3.2 and
BCatRNP5 (GCCGAATTCGCGTTTGGCTGAACCATCAC) with platinum
Pfx DNA polymerase (Invitrogen) according to the manufacturer’s directions.
The resulting PCR product was then digested with HindIII and cloned into the
HindIII site of pcDNA3 (Invitrogen) to yield plasmid pB-cat RNP containing
sequence corresponding to 745 to 1,150 bases of the -catenin mRNA (accession
no. Z19054). Linearized pB-cat RNP was created by digestion with BamHI.
Radioactively labeled RNA probes were synthesized from linearized plasmids
pB-cat RNP and pTRI-GAPDH mouse (Ambion) with a MAXIscript (Ambion)
in vitro transcription kit according to the manufacturer’s directions.
RPA. Ribonuceotide protection assays (RPA) were performed using a Direct
Protect lysate RPA kit (Ambion) according to the manufacturer’s directions.
Briefly, RPA probes were annealed with RNA from 108 cells per reaction
mixture overnight in lysis buffer. The following day samples were digested with
RNase and protease and precipitated. Protected probes were resolved on a 5%
polyacrylamide gel, dried, and imaged using a PhosphorImager (Molecular Dy-
namics). Full-length probes for -catenin and glyceraldehyde phosphate dehy-
drogenase (GAPDH) (465 and 433 bases, respectively) bound to RNA yielded
protected fragments of 406 and 316 bases for the -catenin and GAPDH probes,
respectively.
GST–E-cadherin free -catenin pull-down assay. Glutathione S-transferase
(GST) pull-down assays were performed as described previously (24). GST or
GST–E-cadherin protein was expressed in DH5 Escherichia coli induced with
0.5 mM isopropyl--D-thiogalactopyranoside at 37°C. Cells were pelleted, resus-
pended in ice-cold phosphate-buffered saline, and lysed by sonication in E-
cadherin lysis buffer (10 mM sodium phosphate [pH 7.4], 150 mM NaCl, 1%
NP-40, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 5 g of aprotinin/ml)
on ice. Bacterial lysates were clarified by centrifugation, and GST or GST–E-
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cadherin was purified by binding to glutathione-Sepharose beads for 1 h at 4°C.
The beads were washed three times and resuspended in E-cadherin lysis buffer.
Cells were lysed in E-cadherin lysis buffer containing a protease inhibitor cocktail
for 30 min at 4°C. Protein concentrations in lysates were quantified, and indi-
cated quantities of proteins were precleared with GST-bound Sepharose beads
for 45 min at 4°C and incubated with Sepharose beads bound to GST–E-cad-
herin. After 1 h of incubation at 4°C, the beads were washed three times and
collected by centrifugation. Bound proteins were eluted in SDS sample buffer
and separated via SDS-PAGE and transferred to Immobilon P. Western blotting
was carried out using antibodies as described above.
RESULTS
-Catenin levels in EBV-positive and EBV-negative cell
lines. Increased -catenin levels and activities in lymphocyte
cell lines have recently been described in EBV-infected BL
cells with type III latency compared with those with type I
latency. To determine if EBV consistently affects -catenin
regulation, -catenin levels were determined in EBV-positive
and -negative cell lines. This survey of EBV-positive and -neg-
ative lymphocyte cell lines revealed an increase in total and
free -catenin in all EBV-positive cells (Fig. 1). Increased
-catenin was detected in whole-cell lysates in the EBV-neg-
ative cell lines BJAB and Jurkat but not in DG75 and HL60
cells. All EBV-positive cell lines contained detectable levels of
-catenin, with B95-8 having the greatest total -catenin, CB-
B95-8 and P3HR1 having intermediate levels, and RAJI cells
with low levels. To assess levels of -catenin that were not
bound to axin or E-cadherin complexes, a GST–E-cadherin
fusion protein was used to bind free -catenin. Elution of
bound protein and Western blotting revealed that P3HR1 and
RAJI, in contrast to findings for total -catenin levels, had the
highest levels of free -catenin, while B95-8 and CB-B95-8 had
less but still easily detectable levels in GST–E-cadherin–bound
fractions. All of the EBV-positive cell lines examined had high
levels of total and free -catenin levels, whereas only two of the
four EBV-negative cell lines had high levels of total and free
-catenin. Mutations that stabilize and activate -catenin that
occur in the development of a number of malignancies have
been described, and similar mutations may have occurred dur-
ing tumor development or may be selected for during the
passage of cell lines.
Increased free -catenin in EBV-infected BL cells. To de-
termine whether -catenin is increased in cell lines infected
with EBV, converted BL cell lines latently infected with EBV
were examined for -catenin levels. The parental cells, BL30
and BL41, are EBV-negative BL cell lines that have each been
infected with B95-8 or P3HR1 virus to yield BL30/B95-8,
BL30/P3HR1, BL41/B95-8, or BL41/P3HR1. The B95-8-in-
fected cells expressed EBNA2 and most latent proteins, includ-
ing LMP1 (Fig. 2A). In BL30 and infected BL30 cells in the
LMP1 blot, a lower nonspecific band was present in all chan-
nels with the LMP1-specific upper band present in the B95-8-
infected cells. BL30 and BL41 cells infected with P3HR1 virus,
FIG. 1. Total and free -catenin in EBV-negative and -positive cell
lines. (Upper) Ten micrograms of total cell lysates from EBV-negative
cells, BJAB, DG75, HL60, and Jurkat, and EBV-positive cells, B95-8,
cord blood infected with B95-8 virus (CB-B95-8), P3HR1, and RAJI,
were analyzed by Western blotting for total -catenin expression.
(Lower) Free -catenin was determined by incubation of 200 g of
whole-cell lysate with GST–E-cadherin fusion protein. Bound proteins
were then eluted and analyzed by Western blotting for -catenin.
FIG. 2. Total and free -catenin in converted BL cell lines. EBV-negative BL cell lines (BL30 and BL41) and parental cell lines infected with
EBV strain B95-8 (BL30/B95-8 and BL41/B95-8) or P3HR1 (BL30/P3HR1 and BL41/P3HR1) were analyzed by Western blotting. Fifty micro-
grams of total cell lysate was analyzed for latent EBV proteins EBNA2 and LMP1 (A) or -catenin and actin (B). (B, lower panel) Free -catenin
from 200 and 250 g of protein from BL30 and BL41 cell lines, respectively, was determined using a GST–E-cadherin pull-down assay followed
by Western blotting of bound proteins.
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which has been shown to contain a genomic deletion in the
EBNA2 gene, do not express EBNA2 or LMP1 but do express
EBNA3 (31). In BL30 cells infected with B95-8 and P3HR1
virus, there was an increase in total -catenin levels (Fig. 2B).
A corresponding increase in free -catenin levels was also
detected in the B95-8-infected cells compared to parental
BL30 cells. In the BL41 cells, there was an increase in both
total and free -catenin upon B95-8 infection and a slight
increase in the P3HR1-infected cell line. These data revealed
an increase in -catenin levels not only in EBV-positive cells
compared to EBV-negative cells but also in cells infected with
EBV compared to parental cell lines.
Cytoplasmic localization of -catenin. Activation of wnt sig-
naling leads to stabilization and nuclear localization of -cate-
nin. To determine if there was increased nuclear -catenin in
EBV-infected cell lines, BL30 and BL41 cells as well as EBV-
infected counterparts were fractionated into cytoplasmic and
nuclear fractions and -catenin levels were determined by
Western blotting (Fig. 3). Although increased total -catenin
was detected in both of the infected BL30 cell lines, the in-
creased -catenin in the B95-8-infected BL30 cells was in the
cytoplasmic fraction, while in the P3HR1-infected BL30 cells a
somewhat smaller cytosolic increase was accompanied by an
increase in the nuclear fractions (Fig. 3). Similarly, the in-
creased -catenin in the infected BL41 cell lines was limited to
the cytoplasmic fraction for B95-8-infected cells, and -catenin
levels were not significantly increased in the cytoplasmic or
nuclear fractions of P3HR1-infected BL41 cells. Actin levels
were evaluated to determine equivalent loading, while detec-
tion of GRP78, an endoplasmic reticulum protein, indicated
nuclear purity (bottom panel, upper band). Although the actin
levels of the BL41 compared to the B95-8-infected BL41 cells
were somewhat lower, the GRP78 panel confirmed only slight
differences in loading between the two lanes and -catenin
levels were consistent with total levels seen in Fig. 2. BL30 and
BL41 cell lines infected with B95-8 virus had increased cyto-
plasmic -catenin, while P3HR1-infected cells had a smaller
nuclear increase. These data indicate that EBV infection of BL
cells increases -catenin with minimal effects on nuclear local-
ization.
To determine if transcription of -catenin is altered in EBV-
infected cells, RNA was isolated from parental BL30 and well
as B95-8- and P3HR1-infected cell lines and was then allowed
to anneal to labeled RNA probes for -catenin and GAPDH
messages. RNase protection of bound RNAs and resolution
via PAGE revealed that compared with control GAPDH mes-
sage, the RNA levels of -catenin in the presence or absence
of infection with either of the EBV viruses were unchanged
(Fig. 4). These data indicate that the effects of EBV upon
-catenin are posttranscriptional.
-Catenin and P-GSK3 in lymphocyte cell lines. The in-
creased levels of total -catenin in cell lines suggest that EBV
may affect the regulation of -catenin. However, most of these
cell lines were established from BL tumors, have been exten-
sively passaged, and likely have accumulated additional muta-
tions that affect -catenin regulation. To assess the effect of
EBV on -catenin in recently transformed cell lines, low-pas-
sage LCLs were examined for -catenin levels and localization.
Two sets of uninfected PBL before and after infection with
EBV strain B95-8 were analyzed by Western blotting for
EBNA2 and LMP1, and results indicated that the LCLs ex-
pressed the EBV latent proteins LMP1 and EBNA2 (data not
shown). Previous studies have shown that -catenin is not
detected in normal resting PBL (48), T cells (3), monocytes
(47), or macrophages (27) and is dispensable for hematopoie-
sis and lymphopoiesis (4). Confirming these previous findings,
-catenin was not detected in the whole-cell lysate for PBL
5000 (Fig. 5). In contrast, the EBV-infected lymphocytes had
high levels of -catenin in the whole-cell lysates (Fig. 5). Anal-
ysis of the fractionated LCLs revealed that the increase in
-catenin was completely cytoplasmic, with trace levels of nu-
clear -catenin (Fig. 5). Because of limited quantities of PBL
material, whole-cell extracts of the LCLs were diluted in serial
twofold dilutions to aid with comparisons.
A critical regulator of -catenin is GSK3, which is inacti-
vated by phosphorylation, resulting in -catenin stabilization.
FIG. 3. -Catenin localization in converted BL cell lines. BL30 (A) and BL41 (B) cell lines were fractionated into nuclear and cytoplasmic
fractions, and 50 g of protein for each fraction was analyzed by Western blotting for -catenin, actin, and GRP78. Actin was used as a loading
control, and GRP78, an endoplasmic reticulum chaperone, was used as an indication of nuclear purity.
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Both of the EBV-infected LCLs had readily detectable phos-
phorylated P-GSK3 (Fig. 5). Surprisingly, high levels of P-
GSK3 were present in the nucleus of both LCL 5000 and
5077. LCL 5000 also had relatively high levels of P-GSK3 in
the cytoplasm, whereas LCL 5077 contained very little cyto-
plasmic P-GSK3. The detection of the endoplasmic reticulum
marker GRP78 only in the cytoplasm confirmed the purity of
the nuclear fractions and indicated that the nuclear P-GSK3
did not represent cytoplasmic contamination. These data re-
vealed that EBV has striking effects on -catenin levels and
GSK3 localization, with elevated -catenin in the cytoplasm
but not the nucleus and high levels of inactivated P-GSK3 in
the nucleus.
To determine if the phosphorylation of GSK3 by EBV in
LCLs was dependent upon PI3K signaling, the LCLs were
treated with the PI3K inhibitor LY294002 for 24 h and then
fractionated. Western blotting was performed, and the levels of
-catenin and P-GSK3, as well as of actin, GRP78, and
PARP, were determined. Levels of nuclear and cytoplasmic
-catenin and P-GSK3 were unchanged in the presence of
LY (Fig. 6). Equal actin levels indicated equal loading between
DMSO- and LY-treated samples, and the endoplasmic reticu-
lum marker GRP78 and nuclear marker PARP confirmed the
purity of the cytoplasmic and nuclear fractions, respectively.
These data revealed that the increased cytoplasmic -catenin
and nuclear P-GSK3 were independent of PI3K and that
inactivation of GSK3 by phosphorylation did not result in the
accumulation of nuclear -catenin in this context.
DISCUSSION
In this study, comparisons of EBV-negative versus EBV-
positive cell lines, transformed cells infected with EBV versus
parental uninfected cells lines, and LCLs transformed with
EBV versus PBL starting material revealed that B lymphocytes
infected with EBV contain elevated levels of total, free, and
cytoplasmic -catenin. There was also a dramatic translocation
of phosphorylated and inactivated GSK3 to the nuclei of
LCLs.
These findings confirmed the -catenin levels reported in a
previous study involving Jurkat and HL60 cells (3). Those
authors determined that increased -catenin was important for
the growth properties of Jurkat cells and that inhibition of
-catenin led to cell death. In contrast, -catenin levels and
activity were not important for the growth and viability of
HL60 cells. The detection of increased cytoplasmic -catenin
in both EBV-converted BL cell lines and LCLs transformed by
FIG. 4. RNase protection of -catenin RNA in converted BL cells.
RNA from BL30 and infected BL30/B95-8 (B95-8) and BL30/P3HR1
(P3HR1) cells was purified and analyzed by RPA for -catenin and
GAPDH mRNA. Full-length probes for -catenin and GAPDH (465
and 433 bases, respectively) are shown in the no-RNase lanes. No-
target lanes contained probes reacted with RNase in the absence of
cellular RNA. Other lanes contained the indicated cellular RNA
bound to the probe and reacted with RNase to yield protected frag-
ments of 406 and 316 bases for the -catenin and GAPDH probes,
respectively.
FIG. 5. -Catenin and phosphorylated GSK3 levels and localiza-
tion in LCLs. PBL starting material and LCLs transformed with EBV
were analyzed by Western blotting. Nuclear, cytoplasmic, and whole-
cell extracts of LCL 5000 and LCL 5077 (25 g each) and whole-cell
extract of PBL 5000 (50 g) were analyzed for -catenin, actin,
GRP78, P-GSK3, and total GSK3. Whole-cell extracts were diluted
as indicated in serial twofold dilutions.
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EBV indicate that latent EBV infection induces the cytoplas-
mic accumulation of -catenin.
A recent study described increased -catenin levels in the
presence of EBV type III latency in BL cell lines and reported
a five- to sevenfold increase in Tcf/Lef reporter plasmid acti-
vation (43). However, EBV-negative cells were not examined,
and the cellular localization of -catenin was not determined.
The results presented here indicate that -catenin can be de-
tected in BL cell lines infected with B95-8 or P3HR1 virus and
is not limited to type III latency versus type I latency, as
previously described (43). The variability in the effects of EBV
in these cell lines may reflect genetic changes accumulated in
the BL cell lines. Importantly, these data indicate that in EBV-
transformed lymphocytes that have not been established from
BL, the increased -catenin is in the cytoplasm in EBV-in-
fected lymphoid cells, where it would likely have little effect
upon gene expression. The previously reported small increases
found in reporter assays may reflect trace amounts of -catenin
that move to the nucleus. These data are in stark contrast to
those for epithelial cells, where LMP2A induces increased
total -catenin and induces nuclear translocation of -catenin.
In keeping with these observations, nuclear -catenin has been
detected in the epithelial cancer NPC but not in lymphoid
malignancy Hodgkin’s lymphoma (30). These findings suggest
that activation and nuclear translocation of -catenin is an
important aspect of EBV infection of epithelial cells but not in
lymphoid cells.
-Catenin import into and export from the nucleus is a
regulated process (8, 16, 38). Multistep activation of -catenin
in peripheral blood mononuclear cells has been suggested by
other studies. -Catenin/Lef-1 complexes are present in the
nucleus of normal T cells but are transcriptionally inactive;
however, in the transformed T-cell line Jurkat, these com-
plexes are active (36). Chemical treatment of monocytes with
the GSK3 inhibitor lithium results in -catenin stabilization
without gene activation; however, stimulation with lipopolysac-
charide or zymosan induces -catenin stabilization and gene
activation (47). In epithelial cells, mutations or stimuli that
disrupt cellular junctions, of which -catenin is a component,
result in increased cytoplasmic -catenin without activating
gene transcription (19). These data indicate that nuclear trans-
location and activation of -catenin require other cellular stim-
uli in addition to stabilization.
Classical wnt signaling converges on -catenin bound in a
complex that includes APC, axin, and GSK3. Phosphoryla-
tion of GSK3 results in the stabilization of -catenin and its
translocation to the nucleus. In the present study, phosphory-
lated GSK3 was localized to the nucleus without a corre-
sponding increase in nuclear -catenin. This finding suggests
that the nuclear P-GSK3 may result in increased cytoplasmic
-catenin stability without inducing nuclear translocation of
-catenin. Nuclear GSK3 binds, phosphorylates, and stimu-
lates proapoptotic activity of p53 (51, 52). It is possible that the
inactivated GSK3 in the nucleus might bind to p53 and pre-
vent apoptosis. In support of this is the fact that activation of
Akt, which phosphorylates and inactivates GSK3, inhibits
p53-mediated apoptosis (26, 39, 56). LMP1 has been shown to
specifically inhibit p53-mediated apoptosis, and this may be
due to binding of GSK3 to p53 (10). Another pathway regu-
lated by GSK3 is the Notch pathway, which is important for
hematopoetic development (25). A reduction in GSK3 levels
or activity resulted in a marked reduction in NotchIC levels
(9). The presence of inactivated, phosphorylated GSK3 in the
nucleus of EBV-infected cells likely affects other critical path-
ways.
GSK3 is able to phosphorylate and regulate a number of
cellular targets other than -catenin. GSK3 was originally
identified for its ability to phosphorylate and inhibit glycogen
synthase. Differential regulation of GSK3 by insulin and wnt
has been examined (2, 7). Treatment of cells with insulin leads
to the phosphorylation and inactivation of GSK3 in a PI3K-
and Akt-dependent pathway without increasing -catenin. In
the same cells, treatment with wnt leads to the inactivation of
GSK3 and to stabilization and increased -catenin. The data
presented here indicate that EBV regulates GSK3 by yet
another mechanism. Phosphorylation of GSK3 in EBV-in-
fected LCLs is independent of PI3K signaling and is distinct
from pathways leading to activation and nuclear localization of
-catenin.
In this study neither accumulation of cytoplasmic -catenin
nor nuclear-phosphorylated GSK3 was affected by the inhi-
bition of PI3K, suggesting that -catenin activation in EBV-
infected cells may involve multiple steps. The first step in
-catenin activation would involve cytoplasmic stabilization of
the protein in a PI3K-independent pathway. Inhibition of PI3K
FIG. 6. -Catenin and P-GSK3 are unaffected by inhibition of
PI3K. LCL 5000 was grown to 3  106 cells/ml, separated into equal
volumes, and then diluted twofold with fresh medium containing either
PI3K inhibitor, 50 M LY294002 (LY), or DMSO vehicle control and
grown for 24 h. Cells were then harvested, fractionated, and analyzed
by Western blotting for -catenin, actin, GRP78, P-GSK3, and
PARP. Quantities of protein used were 100, 40, and 80 g for whole-
cell, nuclear, and cytoplasmic fractions, respectively.
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in the presence of LMP2A resulted in a block in the nuclear
translocation of -catenin but did not block the cytoplasmic
stabilization (29). In accordance with those data, inhibition of
PI3K also did not block the cytoplasmic accumulation of
-catenin in the present study. LMP2A has been shown to
interact with the Nedd4 family of ubiquitin ligases (17, 18, 54).
Modulation of the activity of ubiquitin ligases could regulate
and stabilize -catenin in the cytoplasm of EBV-infected cells.
Inhibition of deubiquitinating activity in the cell lysates of type
III-infected cells resulted in decreased -catenin (43). This was
not unexpected, as the turnover of many cellular proteins is
regulated by a balance of ubiquitinating and deubiquitinating
enzymes and decreased levels of many proteins by inhibition of
deubiquitination would be expected. The first step in -catenin
activation in EBV-infected cells likely occurs via PI3K-inde-
pendent stabilization of -catenin by regulation of ubiquitina-
tion pathways.
The second step in the activation of -catenin could occur at
the level of nuclear import. In epithelial cells expressing
LMP2A, the PI3K pathway was required for the nuclear trans-
location of -catenin (29). However, the data presented here
indicate that in transformed lymphocytes the increased -cate-
nin is not nuclear. In contrast, GSK3 is phosphorylated, in-
activated, and targeted to the nucleus.
The importance of -catenin and GSK3 during herpesvirus
infection has been identified in several studies. The Kaposi’s
sarcoma-associated herpesvirus latency-associated nuclear an-
tigen protein has been shown to affect nuclear translocation of
GSK3, and EBV LMP2A activates PI3K, leading to GSK3
phosphorylation. This study reveals that in lymphocytes latent
infection with EBV affects the cytoplasmic levels of -catenin
and nuclear translocation and phosphorylation of GSK3. It
will be important to determine how EBV gene expression
affects GSK3 phosphorylation and intracellular localization
and to identify the targets and pathways affected by the nuclear
P-GSK3 and possibly the cytoplasmic -catenin.
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